Transient expression of the CRISPR-Cas9 machinery is desirable to reduce the risks of off-targets and immune responses. Electroporation of Cas9 ribonucleoproteins (RNPs) is the most common delivery method to achieve transient Cas9 expression. Recently, retroviral capsids have been used for delivering Streptococcus pyogenes Cas9 RNPs, in which Cas9 was fused to the viral proteins. The fusion strategy may cause relative low capsid assembly efficiency. We recently developed virus-like particles (VLPs) consisting of lentiviral capsid and Staphylococcus aureus Cas9 RNPs using the specific interactions between aptamer and aptamer-binding protein (ABP), and obtained near-normal capsid assembly efficiency. Here we test whether highly active Streptococcus pyogenes Cas9 (SpCas9) RNP VLPs can be generated with high efficiency by aptamer/ABP interaction. We found that by optimizing the locations and types of aptamer used for single guide RNA modification, highly active SpCas9 RNP VLPs can be generated efficiently. VLP-delivered SpCas9 generated lower off-target insertions and deletions than SpCas9 RNPs delivered by electroporation. VLPs containing Cas9 from different species and targeting multiple genes can be efficiently prepared in single-particle preparation. Multiple-target VLPs were more efficient than the combination of single-target VLPs for simultaneous targeting of multiple genes. Thus, in addition to better safety features, the Cas9 VLPs are especially suited for multiplex genome editing. In summary, our VLPs offer safe, efficient, and flexible multiplex genome editing.
Get full access to this article
View all access options for this article.
References
1.
ShalemO, SanjanaNE, HartenianE, et al.Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343:84–87. DOI: 10.1126/science.1247005.
2.
HsuPD, ScottDA, WeinsteinJA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013; 31:827–832. DOI: 10.1038/nbt.2647.
3.
KimS, KimD, ChoSW, et al.Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014; 24:1012–1019. DOI: 10.1101/gr.171322.113.
4.
FarboudB, JarvisE, RothTL, et al. Enhanced genome editing with Cas9 ribonucleoprotein in diverse cells and organisms. J Vis Exp. 2018:57350. DOI: 10.3791/57350.
5.
ChoiJG, DangY, AbrahamS, et al.Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016; 23:627–633. DOI: 10.1038/gt.2016.27.
6.
MangeotPE, RissonV, FusilF, et al.Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun. 2019; 10:45. DOI: 10.1038/s41467-018-07845-z.
7.
IndikovaI, IndikS.Highly efficient ‘hit-and-run’ genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts. Nucleic Acids Res. 2020; 48:8178–8187. DOI: 10.1093/nar/gkaa561.
8.
LyuP, Javidi-ParsijaniP, AtalaA, et al.Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient ‘hit-and-run’ genome editing. Nucleic Acids Res. 2019; 47:e99. DOI: 10.1093/nar/gkz605.
9.
HattmanS, NewmanL, MurthyHMK, et al.Com, the Phage Mu-Mom translational activator, is a zinc-binding protein that binds specifically to its cognate messenger-Rna. P Natl Acad Sci USA. 1991; 88:10027–10031. DOI: 10.1073/pnas.88.22.10027.
10.
WulczynFG, KahmannR. Translational stimulation: RNA sequence and structure requirements for binding of Com protein. Cell. 1991; 65:259–269.
11.
ZalatanJG, LeeME, AlmeidaR, et al.Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. 2015; 160:339–350. DOI: 10.1016/j.cell.2014.11.052.
12.
GrigorovB, DecimoD, SmagulovaF, et al.Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc fingers. Retrovirology. 2007; 4:54. DOI: 10.1186/1742-4690-4-54.
13.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337:816–821. DOI: 10.1126/science.1225829.
14.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339:819–823. DOI: 10.1126/science.1231143.
15.
ChoSW, KimS, KimJM, et al.Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013; 31:230–232. DOI: 10.1038/nbt.2507.
16.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science. 2013; 339:823–826. DOI: 10.1126/science.1232033.
17.
JinekM, EastA, ChengA, et al.RNA-programmed genome editing in human cells. Elife. 2013; 2:e00471. DOI: 10.7554/eLife.00471.
18.
LuB, Javidi-ParsijaniP, MakaniV, et al.Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. Nucleic Acids Res. 2019; 47:e44. DOI: 10.1093/nar/gkz093.
19.
Javidi-ParsijaniP, NiuG, DavisM, et al.No evidence of genome editing activity from Natronobacterium gregoryi Argonaute (NgAgo) in human cells. PLoS One. 2017; 12:e0177444. DOI: 10.1371/journal.pone.0177444.
20.
WiegersK, RutterG, KottlerH, et al.Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998; 72:2846–2854.
21.
ParkJ, LimK, KimJS, et al.Cas-analyzer: An online tool for assessing genome editing results using NGS data. Bioinformatics. 2017; 33:286–288. DOI: 10.1093/bioinformatics/btw561.
22.
ClementK, ReesH, CanverMC, et al.CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019; 37:224–226. DOI: 10.1038/s41587-019-0032-3.
23.
BrinkmanEK, ChenT, AmendolaM, et al.Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42:e168. DOI: 10.1093/nar/gku936.
24.
Carlson-StevermerJ, AbdeenAA, KohlenbergL, et al.Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing. Nat Commun. 2017; 8:1711. DOI: 10.1038/s41467-017-01875-9.
LyuP, YooKW, YadavMK, et al.Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay. PLoS One. 2020; 15:e0239468. DOI: 10.1371/journal.pone.0239468.
27.
FoutsDE, TrueHL, CelanderDW. Functional recognition of fragmented operator sites by R17/MS2 coat protein, a translational repressor. Nucleic Acids Res. 1997; 25:4464–4473.
28.
LimF, DowneyTP, PeabodyDS. Translational repression and specific RNA binding by the coat protein of the Pseudomonas phage PP7. J Biol Chem. 2001; 276:22507–22513. DOI: 10.1074/jbc.M102411200.
29.
AustinRJ, XiaT, RenJ, et al.Designed arginine-rich RNA-binding peptides with picomolar affinity. J Am Chem Soc. 2002; 124:10966–10967.
30.
KonermannS, BrighamMD, TrevinoAE, et al.Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015; 517:583–588. DOI: 10.1038/nature14136.
31.
MaH, TuLC, NaseriA, et al.Multiplexed labeling of genomic loci with dCas9 and engineered sgRNAs using CRISPRainbow. Nat Biotechnol. 2016; 34:528–530. DOI: 10.1038/nbt.3526.
32.
GilbertLA, LarsonMH, MorsutL, et al.CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154:442–451. DOI: 10.1016/j.cell.2013.06.044.
33.
ChenB, GilbertLA, CiminiBA, et al.Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. 2013; 155:1479–1491. DOI: 10.1016/j.cell.2013.12.001.
34.
MontagnaC, PetrisG, CasiniA, et al.VSV-G-enveloped vesicles for traceless delivery of CRISPR-Cas9. Molecular therapy Nucleic acids. 2018; 12:453–462. DOI: 10.1016/j.omtn.2018.05.010.
35.
AdikusumaF, PiltzS, CorbettMA, et al.Large deletions induced by Cas9 cleavage. Nature. 2018; 560:E8–E9. DOI: 10.1038/s41586-018-0380-z.
36.
EgliD, ZuccaroMV, KosickiM, et al.Inter-homologue repair in fertilized human eggs?. Nature. 2018; 560:E5–E7. DOI: 10.1038/s41586-018-0379-5.
37.
KosickiM, TombergK, BradleyA. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018; 36:765–771. DOI: 10.1038/nbt.4192.
38.
EssletzbichlerP, KonopkaT, SantoroF, et al.Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res. 2014; 24:2059–2065. DOI: 10.1101/gr.177220.114.
39.
FischerK, RieblingerB, HeinR, et al.Viable pigs after simultaneous inactivation of porcine MHC class I and three xenoreactive antigen genes GGTA1, CMAH and B4GALNT2. Xenotransplantation. 2019:e12560. DOI: 10.1111/xen.12560.
40.
HanX, WangM, DuanS, et al.Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci U S A. 2019; 116:10441–10446. DOI: 10.1073/pnas.1902566116.
41.
RenJ, LiuX, FangC, et al.Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017; 23:2255–2266. DOI: 10.1158/1078-0432.CCR-16-1300.
42.
KaminskiR, ChenY, FischerT, et al.Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 Gene Editing. Sci Rep. 2016; 6:22555. DOI: 10.1038/srep22555.
43.
StadtmauerEA, FraiettaJA, DavisMM, et al.CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367. DOI: 10.1126/science.aba7365.
HorlbeckMA, WitkowskyLB, GuglielmiB, et al.Nucleosomes impede Cas9 access to DNA in vivo and in vitro. Elife. 2016; 5. DOI: 10.7554/eLife.12677.
46.
IsaacRS, JiangF, DoudnaJA, et al.Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. Elife. 2016; 5. DOI: 10.7554/eLife.13450.
47.
ChariR, MaliP, MoosburnerM, et al.Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat Methods. 2015; 12:823–826. DOI: 10.1038/nmeth.3473.
48.
Kallimasioti-PaziEM, Thelakkad ChathothK, TaylorGC, et al.Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair. PLoS Biol. 2018; 16:e2005595. DOI: 10.1371/journal.pbio.2005595.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
